Clinical Trial Update: Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of LAVA-1207 in patients with therapy-refractory metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• LAVA-1207

Snippet

Sponsor: Lava Therapeutics | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1 | Status: TERMINATED